Microstructure Imaging Receives FDA Clearance for MICSI-RMT, Bringing Random Matrix Theory Denoising Into Clinical Practice
2024年7月25日 - 2:11AM
ビジネスワイヤ(英語)
Microstructure Imaging, Inc. (MICSI), a YCombinator backed, NYU
Langone Health spinout, is thrilled to announce FDA 510k clearance
for its MICSI-RMT software suite, designed to enhance MRI image
quality. This clearance marks the clinical translation of advanced
MRI research led by Gregory Lemberskiy, CEO, and Benjamin
Ades-aron, CTO.
MICSI-RMT employs a random matrix theory-based algorithm to
significantly improve MRI image quality through the redundancy of
the MRI exam. Unlike traditional AI methods, MICSI-RMT achieves
these remarkable results without the need for external training
data or high-performance GPUs. Additionally, MICSI-RMT includes
processing modules that support weighted linear least squares and
Bayesian fitting techniques to facilitate quantitative analysis of
diffusion weighted imaging. Lastly, MICSI-RMT features cutting edge
DICOM data routing ensuring securing and seamless integration into
medical workflows.
Key Insights from the Clinical Study:
- Improved Image Quality: In a randomized, blinded rater
study, expert neuroradiologists assessed MRI images processed by
MICSI-RMT and standard of care (SOC). The MICSI-RMT processed
images were preferred for their clarity and reduced artifacts,
achieving higher expert image quality scores compared to standard
diagnostic images. Raters found that DTI images processed with
MICSI-RMT had improved visualization of small structures in brain
white matter and improved contrast to distinguish adjacent tissue
types, and for fMRI, more anatomically appropriate activation
maps.
- Significant SNR Improvements: The software demonstrated
notable enhancements in the signal-to-noise ratio (SNR), with
MICSI-RMT showing improvements of up to 4.35x for diffusion MRI
(dMRI) and 1.9x for functional MRI (fMRI).
- Precise Parametric Mapping: dMRI enhancement achieved
notable improvement parameter precision. Specifically, the
precision of ADC maps was improved by over 56.3%.
A New Era in MRI Diagnostics
MICSI-RMT is a significant breakthrough as the first market
solution designed to enhance the signal-to-noise ratio (SNR) for
diffusion and functional MRI. Diffusion MRI involves the
exponential signal suppression for contrast, often resulting in
images with high noise levels. Similarly, the BOLD effect of
functional MRI is only a few percent of the signal, which can
easily be obscured by image noise. Despite the utility of these
modalities in the clinical workflow, MICSI-RMT is the first
solution to directly address the noise problem.
Our enhancements are particularly transformative for
neuroimaging applications where precise imaging is crucial. In
stroke management, especially for lesions of the posterior fossa,
and in neurosurgical planning, the improved clarity and accuracy of
MRI images directly impact medical decisions. Our clinical study
focused on critical improvements in these areas, enabling
clinicians to make more informed decisions based on clearer, more
precise imaging data.
This advancement not only boosts diagnostic accuracy but also
sets a new standard in neurology care, positioning MICSI-RMT as an
essential tool for medical imaging professionals.
Try MICSI-RMT for yourself and see how it can be integrated into
your diagnostic workflow. For more information, to schedule a
demonstration, or to discuss integration options, please visit
www.micsi.com or email info@micsi.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240724321978/en/
Gregory Lemberskiy, PhD Chief Executive Officer MICSI
info@micsi.com 1-917-695-5416 www.micsi.com